FOLH1 and prostate cancer: For prostate cancer, prostate-specific membrane antigen (PSMA) has currently emerged as an attractive target for theranostic development to help individualize prostate cancer treatment and evaluate the effectiveness of treatment and cancer recurrence [5,6].